Brian J P Huntly

Summary

Affiliation: Brigham and Women's Hospital
Country: USA

Publications

  1. ncbi The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
    Jan Cools
    Division of Hematology and the Howard Hughes Medical Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Blood 103:2802-5. 2004
  2. ncbi Leukaemia stem cells and the evolution of cancer-stem-cell research
    Brian J P Huntly
    Brian J P Huntly is at the Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Nat Rev Cancer 5:311-21. 2005
  3. pmc FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia
    Benjamin H Lee
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 12:367-80. 2007
  4. ncbi FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model
    Benjamin H Lee
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Oncogene 24:7882-92. 2005
  5. pmc The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis
    Claudia Scholl
    Division of Hematology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 117:1037-48. 2007
  6. ncbi FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
    Jing Chen
    Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 24:8259-67. 2005
  7. ncbi HOX gene regulation in acute myeloid leukemia: CDX marks the spot?
    Stefan Fröhling
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cell Cycle 6:2241-5. 2007
  8. pmc The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
    Ross L Levine
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Blood 106:3377-9. 2005
  9. pmc Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation
    Jing Chen
    Howard Hughes Medical Institute, Harvard Medical Scgool, Boston, MA, USA
    Blood 106:328-37. 2005
  10. ncbi Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia
    Brian J P Huntly
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Cell 6:199-201. 2004

Collaborators

Detail Information

Publications16

  1. ncbi The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
    Jan Cools
    Division of Hematology and the Howard Hughes Medical Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Blood 103:2802-5. 2004
    ....
  2. ncbi Leukaemia stem cells and the evolution of cancer-stem-cell research
    Brian J P Huntly
    Brian J P Huntly is at the Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Nat Rev Cancer 5:311-21. 2005
    ....
  3. pmc FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia
    Benjamin H Lee
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 12:367-80. 2007
    ..This model provides insights into the consequences of constitutive signaling by an oncogenic tyrosine kinase on hematopoietic progenitor quiescence, function, and cell fate...
  4. ncbi FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model
    Benjamin H Lee
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Oncogene 24:7882-92. 2005
    ....
  5. pmc The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis
    Claudia Scholl
    Division of Hematology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 117:1037-48. 2007
    ....
  6. ncbi FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
    Jing Chen
    Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 24:8259-67. 2005
    ..These data indicate that PKC412 may be a useful molecularly targeted therapy for MM associated with overexpression of FGFR3, and perhaps other diseases associated with dysregulation of FGFR3 or related mutants...
  7. ncbi HOX gene regulation in acute myeloid leukemia: CDX marks the spot?
    Stefan Fröhling
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cell Cycle 6:2241-5. 2007
    ..Taken together, these studies implicate CDX proteins as master regulators of HOX gene regulation in AML...
  8. pmc The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
    Ross L Levine
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Blood 106:3377-9. 2005
    ..These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies...
  9. pmc Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation
    Jing Chen
    Howard Hughes Medical Institute, Harvard Medical Scgool, Boston, MA, USA
    Blood 106:328-37. 2005
    ..These data indicate that engagement of multiple signaling pathways, including PLCgamma-dependent and PLCgamma-independent pathways, is required for full hematopoietic transformation by constitutively activated FGFR3 mutants...
  10. ncbi Blasts from the past: new lessons in stem cell biology from chronic myelogenous leukemia
    Brian J P Huntly
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Cell 6:199-201. 2004
    ....
  11. pmc Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model
    Dimple Bansal
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:16924-9. 2006
    ..Inasmuch as many human leukemias show dysregulated expression of a spectrum of HOX family members, these collective findings also suggest a central role for CDX4 expression in the genesis of acute leukemia...
  12. ncbi MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
    Brian J P Huntly
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Cell 6:587-96. 2004
    ..These data demonstrate that some, but not all, leukemia oncogenes can confer properties of leukemic stem cells to hematopoietic progenitors destined to undergo apoptotic cell death...
  13. ncbi Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Ross L Levine
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 7:387-97. 2005
    ..In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase...
  14. ncbi Targeting cancer stem cells
    Brynn T Kvinlaug
    University of Cambridge, Department of Haematology, Cambridge Institute for Medical Research, Cambridge, CB2 2XY, UK
    Expert Opin Ther Targets 11:915-27. 2007
    ..Finally, the authors give their opinion of the direction in which one must travel to successfully target the CSC and improve treatment outcomes in malignant disease...
  15. ncbi Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
    Peter J Campbell
    Department of Haematology, University of Cambridge, Cambridge, United Kingdom
    Blood 108:3548-55. 2006
    ..In 3 patients the leukemic cells were V617F(-), suggesting that in these patients the leukemia arose in a V617F(-) cell...
  16. doi Leukemia stem cells in acute myeloid leukemia
    Wai In Chan
    Department of Haematology, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
    Semin Oncol 35:326-35. 2008
    ....